QPPV.COM KNOWLEDGE ASSESSMENT

Post-PRAC Regulatory Pathways: CHMP, CMDh and the European Commission

Test your understanding of the concepts covered by What Happens After a PRAC Recommendation? CHMP, CMDh and the European Commission.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why can implementation of one referral be operationally complex for an MAH with nationally authorised products in several Member States?

Each Member State must conduct a completely independent scientific reassessment The company must map the affected national authorisations and complete the applicable procedural and documentation steps in each Member State Nationally authorised products cannot be affected by Union-level safety conclusions CMDh automatically updates every national product-information document without MAH involvement

Question 2 of 10 In a procedure involving nationally authorised medicines, what is the practical significance of CMDh coordination?

It creates a new centrally authorised marketing authorisation It supports consistent implementation of the Union outcome through the affected national marketing authorisations It transfers all national marketing authorisations to EMA It removes Member States from the implementation process

Question 3 of 10 What is the most accurate description of CHMP's role after receiving a PRAC recommendation in an applicable centralised procedure?

CHMP performs only a clerical transmission of the PRAC recommendation CHMP considers the recommendation and assessment report within its own scientific and regulatory remit CHMP replaces PRAC as the committee responsible for all pharmacovigilance signal assessment CHMP implements the recommendation directly through national marketing authorisations

Question 4 of 10 For an Article 20 pharmacovigilance procedure concerning centrally authorised products, which sequence is generally correct?

PRAC recommendation, CMDh position, national implementation, Commission decision PRAC recommendation, CHMP opinion, European Commission decision where required, centralised implementation PRAC recommendation, direct national competent-authority decision, CHMP review PRAC recommendation, European Commission decision, PRAC re-assessment, CHMP opinion

Question 5 of 10 Which statement best distinguishes a CHMP opinion from a European Commission decision?

A CHMP opinion is the committee's formal conclusion, whereas a Commission decision is the legally binding Union act where required A CHMP opinion is legally binding on all Member States, whereas a Commission decision is advisory A CHMP opinion applies only to safety signals, whereas a Commission decision applies only to quality matters There is no substantive distinction once the CHMP opinion is adopted

Question 6 of 10 Which statement best describes implementation for a centrally authorised product after a final applicable Union decision?

The MAH may implement any wording it considers scientifically preferable The outcome must be translated into the authorised status and controlled product information of the centrally authorised product Implementation is performed exclusively by each national competent authority No implementation is needed if the PRAC recommendation was already published

Question 7 of 10 An inspection team asks when a recommended safety action became a binding obligation and when implementation was completed. Which control would best support the answer?

A record distinguishing the recommendation date, final legal instrument, implementation start and completion evidence A copy of the product's original development plan A list of all adverse events received before the referral A statement that EMA changed the label

Question 8 of 10 Which action best reflects the QPPV's role after a referral outcome changes the recognised safety profile of a product?

Take over all legal decision-making from regulatory affairs Assess the effect on the pharmacovigilance system, including signal management, case follow-up and risk-management activities Approve the Commission decision on behalf of the Member States Limit involvement to checking whether the product name is correctly spelled

Question 9 of 10 Which statement is the most precise way to describe a completed referral?

EMA changed the medicine PRAC assessed the safety issue, the applicable committee adopted its conclusion, the legally operative act was adopted where required, and the outcome was implemented CMDh issued a new central marketing authorisation The European Commission performed the pharmacovigilance assessment

Question 10 of 10 An Article 31 pharmacovigilance referral includes both centrally authorised and nationally authorised products. Which post-PRAC pathway is most appropriate to anticipate?

The recommendation proceeds only to CMDh because nationally authorised products are included The recommendation proceeds to CHMP because centrally authorised products are included, with implementation differing by authorisation type Each product must undergo a separate PRAC assessment with no further Union-level coordination The European Commission automatically adopts the PRAC recommendation without a committee opinion

Post-PRAC Regulatory Pathways: CHMP, CMDh and the European Commission

Cookie Settings